Arvinas’ (ARVN) Neutral Rating Reaffirmed at Wedbush

Wedbush reissued their neutral rating on shares of Arvinas (NASDAQ:ARVN) in a report released on Thursday morning,RTT News reports. They currently have a $9.00 price objective on the stock. Wedbush also issued estimates for Arvinas’ Q1 2026 earnings at ($0.63) EPS and Q2 2026 earnings at ($0.65) EPS.

ARVN has been the topic of several other reports. The Goldman Sachs Group restated a “sell” rating and set a $6.00 price target (down from $8.00) on shares of Arvinas in a research report on Wednesday, October 15th. Weiss Ratings reissued a “sell (e+)” rating on shares of Arvinas in a research report on Wednesday, October 8th. BTIG Research upped their target price on shares of Arvinas from $10.00 to $14.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Piper Sandler reissued an “overweight” rating and set a $16.00 price target on shares of Arvinas in a research report on Tuesday, October 7th. Finally, HC Wainwright decreased their price objective on shares of Arvinas from $24.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, August 7th. Eleven analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Arvinas currently has an average rating of “Hold” and an average price target of $16.34.

Arvinas Stock Up 6.3%

Shares of ARVN traded up $0.63 during trading hours on Thursday, reaching $10.63. 2,600,381 shares of the company traded hands, compared to its average volume of 2,175,635. Arvinas has a 12 month low of $5.90 and a 12 month high of $28.70. The company’s fifty day moving average price is $8.77 and its two-hundred day moving average price is $7.90. The company has a market capitalization of $780.45 million, a price-to-earnings ratio of -13.12 and a beta of 2.38.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.27. The business had revenue of $41.90 million during the quarter, compared to analyst estimates of $29.36 million. Arvinas had a negative net margin of 18.73% and a negative return on equity of 9.58%. Arvinas’s quarterly revenue was down 59.1% compared to the same quarter last year. During the same period last year, the business posted ($0.68) earnings per share. On average, analysts expect that Arvinas will post -3.81 EPS for the current year.

Arvinas declared that its board has authorized a stock repurchase plan on Wednesday, September 17th that permits the company to buyback $100.00 million in outstanding shares. This buyback authorization permits the company to purchase up to 17.9% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling

In other news, Director Briggs Morrison bought 30,000 shares of the stock in a transaction on Monday, September 22nd. The shares were bought at an average price of $7.57 per share, with a total value of $227,100.00. Following the completion of the acquisition, the director owned 76,021 shares in the company, valued at $575,478.97. The trade was a 65.19% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 4.73% of the company’s stock.

Hedge Funds Weigh In On Arvinas

A number of institutional investors and hedge funds have recently made changes to their positions in ARVN. Alyeska Investment Group L.P. bought a new stake in shares of Arvinas during the 1st quarter valued at $12,636,000. Vanguard Group Inc. lifted its position in shares of Arvinas by 18.4% during the 1st quarter. Vanguard Group Inc. now owns 8,362,200 shares of the company’s stock valued at $58,703,000 after buying an additional 1,299,639 shares in the last quarter. Acadian Asset Management LLC grew its stake in shares of Arvinas by 791.1% during the 2nd quarter. Acadian Asset Management LLC now owns 1,427,832 shares of the company’s stock valued at $10,498,000 after acquiring an additional 1,267,593 shares during the period. Philosophy Capital Management LLC purchased a new stake in Arvinas in the 1st quarter worth approximately $6,992,000. Finally, Federated Hermes Inc. raised its stake in Arvinas by 1,965.0% during the 1st quarter. Federated Hermes Inc. now owns 980,674 shares of the company’s stock worth $6,884,000 after acquiring an additional 933,183 shares during the period. Hedge funds and other institutional investors own 95.19% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.